CG Oncology, Inc. SEC filings CGON

CG Oncology, Inc. has 243 filings in SEC EDGAR's recent list, going back to Oct 27, 2023. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 6, 2026 (results of operations, other events). The company's fiscal year ends on December 31.

Form Description Filed Period
424B5 Prospectus supplement Aug 6, 2026 —
S-8 Employee stock plan registration Feb 27, 2026 —
424B5 Prospectus supplement Jan 13, 2026 —
S-3ASR Automatic shelf registration Mar 28, 2025 —
424B4 Prospectus Dec 13, 2024 —
S-1/A Amended registration statement Dec 11, 2024 —
S-1 Registration statement Dec 11, 2024 —
S-8 Employee stock plan registration Jan 26, 2024 —
424B4 Prospectus Jan 25, 2024 —
S-1MEF Filing Jan 24, 2024 —
S-1/A Amended registration statement Jan 23, 2024 —
S-1/A Amended registration statement Jan 18, 2024 —
S-1 Registration statement Jan 2, 2024 —

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
CGON (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Dallas, TX
SEC filer status
Large accelerated filer
SEC CIK
1991792

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.